...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Antibiotics: An International Journal >Development of a molecule-recognized promoter DNA sequence for inhibition of HER2 expression.
【24h】

Development of a molecule-recognized promoter DNA sequence for inhibition of HER2 expression.

机译：抑制HER2表达的分子识别的启动子DNA序列的发展。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

HER2 (also known as ERBB2, NEU) is one of the transmembrane tyrosine kinase receptor genes belonging to the EGFR family. Its expression is kept at a very low level in normal cells, but in tumors, over 30% of breast cancer is detected with extremely high levels of HER2 mRNA. The overexpression of HER2 is frequently accompanied by tumor migration, low sensitivity to chemotherapy and an adverse prognosis.1"5 Earlier studies have shown that HER2 protein over-expression and accumulation occurred mainly because of the resulting transcriptional deregulation, not because of the mRNA stabilization6 and transcription-regulating sequences located in the upstream of the HER2 coding region.7 Thus, the inhibition of HER2 transcription has been considered a useful method of cancer therapy. However, there is no report that a chemical reagent decreases HER2 transcription in cancer cells. Hence, a compound that pre-transcriptionally deregulates HER2 expression needs to be evaluated as a potentially useful HER2 silencer for cancer therapy.
机译：HER2（也称为ERBB2，NEU）是属于EGFR家族的跨膜酪氨酸激酶受体基因之一。它在正常细胞中的表达保持在非常低的水平，但是在肿瘤中，检测到30％以上的乳腺癌中HER2 mRNA的水平很高。 HER2的过表达通常伴随着肿瘤迁移，对化学疗法的敏感性低和不良的预后。1“ 5较早的研究表明，HER2蛋白的过表达和积累主要是由于转录失调，而不是因为mRNA的稳定6。 7因此，抑制HER2的转录被认为是一种有效的癌症治疗方法，但是，没有化学试剂降低癌细胞中HER2的转录的报道。因此，转录前上调HER2表达的化合物需要被评估为可能用于癌症治疗的HER2沉默子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号